IQVIA Holdings Inc Dossier
|
SectorHealth Care IndustryLife Sciences Tools & Services Beta (adjusted)1.12 Intrinsic Value $241.69median of 6 methods · middle span $210-$258based on filings through 31 Mar 2026 Market Price $260.72Price as of 1 Oct 2026 Near fair valueIntrinsic value is 7% below the market price −50% · IV below pricenear fair value ±15%IV above price · +50% Data confidence Sign in to view data confidence Market Cap $42.9B Enterprise Value $56.8B Shares Outstanding 165.9M diluted Moat Rating Narrow Next Earnings Date27 Oct 2026 All prices and values are periodic snapshots, not live quotes. Source dates are shown for reference. ThesisStreet consensus, scenarios, merits, risks, and invalidation triggers Thesis Summary IQVIA entered the second half of 2026 with broad operating momentum: second-quarter revenue rose 8.7%, both operating segments grew more than 8% at constant currency, R&D Solutions generated $3.15 billion of net new bookings and a 1.22x book-to-bill ratio, and management raised full-year revenue, Adjusted EBITDA and adjusted diluted EPS guidance. The positive case rests on converting the $34.2 billion R&D Solutions backlog, sustaining commercial growth and monetizing IQVIA.ai. The principal offsets are elevated leverage, contract-cancellation and backlog-conversion risk, and substantial privacy, cybersecurity and regulatory exposure. This section is the 12-month view: analyst targets and the probability-weighted scenarios built from them. The intrinsic value at the top of this page answers a different question: what the business is worth today. Street view · analyst 12-month targets Low · most bearish analyst$240.00 Mean target$275.17 High · most bullish analyst$300.00 Street targets sit above today's price; our intrinsic value sits below it. Different horizons, different questions. Our research · scenarios, merits, risks, and invalidation triggersResearch as of 2 Sep 2026 Scenarios · 12-month scenario targets Bear CaseDownside scenario $240.0020% Clinical-development customers delay or cancel projects, book-to-bill falls below 1.0x, backlog conversion weakens and elevated leverage limits financial flexibility. Data-access restrictions, privacy regulation or cybersecurity failures could also impair IQVIA's data and technology offerings. Base CaseCentral scenario $275.1755% Matches the consensus meanIQVIA performs within its raised 2026 guidance of $17.275-$17.475 billion in revenue, $4.000-$4.050 billion in Adjusted EBITDA and $12.80-$13.00 in adjusted diluted EPS. R&D Solutions demand remains constructive but normalizes from the exceptional second-quarter bookings level, while leverage improves only gradually. Bull CaseUpside scenario $300.0025% Sustained R&D Solutions bookings and faster backlog conversion support growth into 2027, Commercial Solutions maintains high-single-digit constant-currency expansion, and IQVIA.ai adoption broadens from its reported foothold among 19 of the top 20 pharmaceutical companies. Continued execution above guidance could produce further earnings upgrades. Scenarios are anchored to street consensus at the research date, with our probabilities and rationale. Key Investment Merits
Key Investment Risks
All scenarios are estimates and subject to change. Past performance is not indicative of future results. Quality Pillars MembersThis section is available to registered members. Create a free account or sign in to unlock the full breakdown. Explore this dossierValuationIntrinsic value, the six-method breakdown, peer medians, and your assumptions sandbox.Financial SnapshotRevenue, profitability, returns, balance sheet, dividends, and the filing-level detail.Qualitative AnalysisBusiness overview, strategic initiatives, and mergers, acquisitions & partnerships.Outlook & Key DatesForward estimates, reporting calendar, and the monitoring framework. |